Department of Virology, Erasmus MC, Rotterdam, The Netherlands.
J Infect Dis. 2011 Sep 1;204(5):777-82. doi: 10.1093/infdis/jir397.
A retrospective nationwide study on the use of intravenous (IV) zanamivir in patients receiving intensive care who were pretreated with oseltamivir in the Netherlands was performed. In 6 of 13 patients with a sustained reduction of the viral load, the median time to start IV zanamivir was 9 days (range, 4-11 days) compared with 14 days (range, 6-21 days) in 7 patients without viral load reduction (P = .052). Viral load response did not influence mortality. We conclude that IV zanamivir as late add-on therapy has limited effectiveness. The effect of an immediate start with IV zanamivir monotherapy or in combination with other drugs need to be evaluated.
在荷兰进行了一项关于静脉（IV）扎那米韦在接受重症监护的患者中使用的回顾性全国性研究，这些患者在接受奥司他韦预处理。在病毒载量持续降低的 13 名患者中的 6 名中，与病毒载量未降低的 7 名患者（范围为 6-21 天）相比，开始静脉注射扎那米韦的中位时间为 9 天（范围为 4-11 天）（P =.052）。病毒载量反应并不影响死亡率。我们得出结论，作为晚期附加治疗的 IV 扎那米韦效果有限。需要评估立即开始使用 IV 扎那米韦单药治疗或与其他药物联合治疗的效果。
